Abstract

PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing

Author(s): Allen Loyd V Jr

Issue: Mar/Apr 2018 - Volume 22, Number 2

View All Articles in Issue

Page(s): 92

Download in electronic PDF format for $75

Abstract

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Mar/Apr 2018 Pg. 92	PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing Author(s): Allen Loyd V Jr
Mar/Apr 2018 Pg. 125-126	IACP Legislative/Regulatory Update: The International Academy of Compounding Pharmacists Testifies at U.S. House of Representatives' Energy & Commerce Health Subcommittee Pharmacy Compounding Hearing Author(s): Blankenship Cynthia
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Mar/Apr 2015 Pg. 104-106	Standing Together Fixing the Drug Quality and Security Act Author(s): Miller David G
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Sep/Oct 2015 Pg. 389-390	Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Author(s): Allen Loyd V Jr
Jan/Feb 2014 Pg. 35-36	U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Author(s): Miller David G
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Jul/Aug 2020 Pg. 296-297	Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Author(s): Brunner Scott
Sep/Oct 2021 Pg. 358-362	Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Author(s): Cabaleiro Joe
Nov/Dec 2016 Pg. 457-458	U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Author(s):
Jul/Aug 2007 Pg. 326-327	Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Author(s): Kupiec Tom, Kemp Jesse
Jul/Aug 2007 Pg. 350-351	PostScription: Thousands of Unapproved New Drugs are on the U.S. Market, Part 1 Author(s): Allen Loyd V Jr
May/Jun 2014 Pg. 208	The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Author(s): Miller David G
Mar/Apr 2017 Pg. 95-102	U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Author(s): Yoch Doug
Jan/Feb 2019 Pg. 32-33	U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Nov/Dec 2015 Pg. 453-463	Applying Quality of Design Concepts to Pharmacy Compounding Author(s): Timko Robert J
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
Sep/Oct 2015 Pg. 377-380	The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists Author(s): Parks Kenneth Chase, Bernard Brian, Cogdill Christopher Blake